Adenosine amine congener NEW
| Price | $67 | $163 | $247 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Adenosine amine congener | CAS No.: 96760-69-9 |
| Purity: 97.86% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Adenosine amine congener |
| Description | Adenosine amine congener (ADAC) (ADAC) is an agonist of selective A1 adenosine receptor,. |
| Animal Research | Adenosine amine congener (ADAC)??(25-300 μg/kg) was administered intraperitoneally to Wistar rats (8-10 weeks old) at intervals (6-72 hours) after exposure to traumatic noise (8-16 kHz, 110 dB sound pressure level, 2 hours). Hearing sensitivity was assessed using auditory brainstem responses (ABR) before and 12 days after noise exposure. Pharmacokinetic studies investigated ADAC concentrations in plasma after systemic (intravenous) administration[1]. |
| In vivo | Adenosine amine congener (ADAC) was most effective in the first 24 hours after noise exposure at doses >50 μg/kg, providing up to 21 dB protection (averaged across 8-28 kHz). Pharmacokinetic studies demonstrated a short (5 min) half-life of ADAC in plasma after intravenous administration without detection of degradation products. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 31.25 mg/mL (54.20 mM) |
| Keywords | P1 receptor | otoprotective | Adenosine Receptor | loss | hearing | Inhibitor | apoptotic | Adenosine amine congener | injury | systemic | A1-adenosine | Cochlear | inhibit | Ca2+ | neuroprotective |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Nitrobenzylthioinosine | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Anti-Viral Compound Library | CNS-Penetrant Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $995.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-03 | |
| $0.00/1kg |
VIP3Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2022-10-12 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY